scholarly journals 934 Artificial Liver Support in Children with Fulminant Hepatic Failure: Our Experience

2010 ◽  
Vol 68 ◽  
pp. 467-467
Author(s):  
M Corno ◽  
E Bonanomi ◽  
I Pellicioli ◽  
A Tartufari ◽  
V Corno ◽  
...  
ASAIO Journal ◽  
1996 ◽  
Vol 42 (3) ◽  
pp. 233-235
Author(s):  
KAZUFUMI OKAMOTO ◽  
MITSURO KUROSE ◽  
YOSHITOMO IKUTA ◽  
KENICHI OGATA ◽  
TOSHIKAZU HARADA ◽  
...  

2002 ◽  
Vol 6 (3) ◽  
pp. 208-212 ◽  
Author(s):  
Masakazu Nitta ◽  
Hiroyuki Hirasawa ◽  
Shigeto Oda ◽  
Hidetoshi Shiga ◽  
Kazuya Nakanishi ◽  
...  

2002 ◽  
Vol 25 (10) ◽  
pp. 903-910 ◽  
Author(s):  
H. Bertani ◽  
R. Gelmini ◽  
M.G. Del Buono ◽  
N. De Maria ◽  
M. Girardis ◽  
...  

Artificial liver support is a therapeutic option for subjects with fulminant hepatic failure. Results of these studies suggest a possible favourable effect on this condition. The aim of the present review is to evaluate not the results of the different artificial systems available but the methodology used to achieve these results. A computer and manual search of the literature was performed; 832 pertinent references were retrieved. Seventy-seven were full papers reporting the application of artificial liver support in animals or humans (15 RCTs (3 in humans, 12 in animals), 53 uncontrolled phase I trials, 9 case reports). The results of this review indicate that, although the rationale of artificial liver support as shown by animal studies is acceptable, the widespread use in clinical practice is not justified and a controlled design for the studies on artificial liver support systems is mandatory.


2000 ◽  
Vol 14 (suppl d) ◽  
pp. 79D-84D ◽  
Author(s):  
Paul P Ting ◽  
Achilles A Demetriou

Fulminant hepatic failure is a devastating disease that, despite recent therapeutic advances, continues to be associated with high morbidity and mortality. Orthotopic liver transplantation has emerged as the sole modality of treatment that significantly improves survival. However, the critical shortage of donors precludes timely transplantation for all patients. Consequently, almost half of all patients with fulminant hepatic failure die before a graft becomes available. This has generated interest in developing a system that would support patients until either native liver regeneration occurs or an optimal donor liver can be found. Investigators have used biological, artificial and bioartificial techniques in an attempt to improve survival in liver failure. This article reviews the history, the current state of the art and future directions of artificial liver support.


ASAIO Journal ◽  
1996 ◽  
Vol 42 (3) ◽  
pp. 233-235 ◽  
Author(s):  
Kazufumi Okamoto ◽  
Mitsuro Kurose ◽  
Yoshitomo Ikuta ◽  
Kenichi Ogata ◽  
Toshikazu Harada ◽  
...  

2002 ◽  
Vol 25 (12) ◽  
pp. 1144-1152 ◽  
Author(s):  
R. Sakiyama ◽  
K. Nakazawa ◽  
H. Ijima ◽  
H. Mizumoto ◽  
T. Kajiwara ◽  
...  

We studied the recovery of rats with fulminant hepatic failure (FHF) by treating them with our original hybrid artificial liver support system (HALSS). FHF was induced by a two-thirds partial hepatectomy and 10 minutes of hepatic ischemia. Rats with FHF were treated with a polyurethane foam/spheroid HALSS including 2.0 T 108 hepatocytes for 1 hour (HALSS group, n = 5), and with the same system without hepatocytes in the artificial liver module as a control experiment (sham-HALSS group, n = 3). The level of blood constituents, ammonia, glucose and creatinine, showed no major difference between the two groups at the end of treatment. All rats in the sham-HALSS group died within 5 hours after treatment. However, the level of blood constituents of rats with FHF in the HALSS group improved with time, and all rats in the HALSS group recovered. Liver tissue of rats treated with HALSS showed cell mitosis and improvement from injury. These results indicated that our HALSS has a strong possibility to induce recovery from hepatic failure.


Sign in / Sign up

Export Citation Format

Share Document